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Schistosomiasis is a neglected tropical disease, and after malaria, is the second most
important tropical disease in public health. A vaccine that reduces parasitemia is desirable
to achieve mass treatment with a low cost. Although potential antigens have been
identified and tested in clinical trials, no effective vaccine against schistosomiasis is
available. Y-box-binding proteins (YBPs) regulate gene expression and participate in a
variety of cellular processes, including transcriptional and translational regulation, DNA
repair, cellular proliferation, drug resistance, and stress responses. The Schistosoma
mansoni ortholog of the human YB-1, SMYB1, is expressed in all stages of the parasite
life cycle. Although SMYB1 binds to DNA or RNA oligonucleotides, immunohistochemistry
assays demonstrated that it is primarily localized in the cytoplasm of parasite cells. In
addition, SMYB1 interacts with a protein involved in mRNA processing, suggesting that
SMYB1 functions in the turnover, transport, and/or stabilization of RNA molecules during
post-transcriptional gene regulation. Here we report the potential of SMYB1 as a vaccine
candidate. We demonstrate that recombinant SMYB1 stimulates the production of high
levels of specific IgG1 antibodies in a mouse model. The observed levels of specific IgG1
and IgG2a antibodies indicate an actual protection against cercariae challenge. Animals
immunized with rSMYB1 exhibited a 26% reduction in adult worm burden and a 28%
reduction in eggs retained in the liver. Although proteins from the worm tegument
are considered optimal targets for vaccine development, this study demonstrates that
unexposed cytoplasmic proteins can reduce the load of intestinal worms and the number
of eggs retained in the liver.
Keywords: Schistosoma mansoni , Y-box-binding protein 1, SMYB1, cytoplasmic antigen, vaccine candidates
INTRODUCTION
Schistosomiasis is the second most important neglected tropi-
cal disease causing approximately 280,000 deaths annually (King
et al., 2006; Steinmann et al., 2006; Hotez et al., 2008). The
disease remains endemic in several developing countries, includ-
ing Brazil, where Schistosoma mansoni is the etiologic agent.
The advent of praziquantel was essential to reduce morbidity
and mortality due to schistosomiasis. However, the emergence
of parasite resistant strains has been reported, raising concerns
about the long-term effectiveness of this worldwide available
drug (Doenhoff et al., 2002; Hotez et al., 2010). Therefore, the
development of new drugs and additional control measures are
essential to halt schistosomiasis dissemination. The development
of a vaccine that significantly reduces parasitemia is desirable in
order to allow a mass treatment with high level of protection and
low costs (Chan, 1997; Katz, 1999; McManus, 1999).
Irradiated cercariae used for immunization in experimental
animal models regularly induce>80% of protection (Souza et al.,
1987; Lin et al., 2011; Tian et al., 2013). However, although some
promising antigens have been identified and tested in clinical
trials, no effective vaccine against schistosomiasis is currently
available. Indeed, most of the studied anti-schistosome targets
are tegumental proteins, which directly interact with the host, but
consistently do not show satisfactory protection levels (McManus
and Loukas, 2008). Consequently, WHO has encouraged tests
with new vaccine candidates such as cytoskeletal or cytoplas-
mic proteins which may be used as part of a multivalent vaccine
(Wilson and Coulson, 2006). Additionally, vaccines based on
nuclear/cytoplasmic proteins exhibit less chance to trigger an
allergic response in the vaccinated individuals (Bethony et al.,
2011), as they are not directly exposed to the host immune system.
In this context, the YBPs comprise a family of proteins that
are found in most living organisms (Evdokimova et al., 2006)
and contain a highly conserved nucleic acid-binding domain,
the cold-shock domain (CSD), which possesses great similar-
ity to bacterial cold-shock proteins (Wistow, 1990). In addi-
tion to the CSD, proteins from this family have a variable
C-terminal TAIL domain predominantly composed of basic or
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acid amino acids, which are responsible for either nucleic acid
binding or protein-protein interactions (reviewed by Matsumoto
and Bay, 2005). YBPs were originally identified as proteins
that bind to DNA, RNA, and other proteins (Sommerville and
Ladomery, 1996; Matsumoto and Wolffe, 1998; Valadão et al.,
2002; Evdokimova et al., 2006; Dong et al., 2009; Mihailovich
et al., 2010; Eliseeva et al., 2011). Subsequent studies demon-
strated that YB-1, a member of this family, is a major component
of ribonucleoprotein particles (mRNPs), working on pre-mRNA
splicing, mRNA stability, and translation (Mihailovich et al.,
2010; Brandt et al., 2012). Thus, these proteins regulate gene
expression and participate in a variety of cellular processes,
including transcriptional and translational regulation, induction
of DNA repair, cellular proliferation, drug resistance, and stress
responses to extracellular signals (Kohno et al., 2003; Mihailovich
et al., 2010; Brandt et al., 2012).
In response to stress signals, including low temperatures, drugs
that act on DNA, reactive oxygen species, and UV irradiation, the
YB-1 protein can translocate from the cytoplasm to the nucleus
and participate in gene regulation (Koike et al., 1997; Matsumoto
and Wolffe, 1998; Kohno et al., 2003). One of the Y-box pro-
tein functions has been elucidated by studies of genes that are
repressed in response to YB-1 overexpression in somatic cells.
For example, an increase in cellular levels of the human YB-1
protein transcriptionally represses interferon-mediated activation
of MHC class II genes (Ting et al., 1994). Subsequent analysis
established that YB-1 stimulates the formation of single-stranded
regions at the Y-box element (an inverted CCAAT motif) in
a MHC class II gene promoter, preventing the loading and/or
function of other transacting factors (MacDonald et al., 1995).
In addition, it was reported that a synthetic protein can inter-
act with YB-1, stimulating its translocation from the cytoplasm
to the nucleus, where YB-1 binds to the promoters of collagen
genes and suppresses their transcription, preventing the progres-
sion of systemic and hepatic fibrosis (Higashi et al., 2003a,b, 2011;
Hasegawa et al., 2009). Currently, a number of genes involved in
innate immune response processes and inflammation have been
reported to be down- or up-regulated by the YB-1 protein (see the
review by Raffetseder et al., 2012).
SMYB1 is a S. mansoni protein that belongs to the YBP family
and was described by Franco et al. (1997). Due to the similar-
ity between SMYB1 and Y-box proteins from other organisms,
and the importance of these proteins in the control of gene
expression, our group conducted several studies to characterize
the SMYB1 protein. We reported that (i) the protein binds to
double- or single-stranded DNA oligonucleotides, with a pref-
erence for sequences containing the CCAATT motif, (ii) the
protein is expressed in all stages of the parasite life cycle, (iii)
SMYB1 interacts with proteins involved in mRNA processing,
and (iv) SMYB1 has a cytoplasmic localization (Franco et al.,
1997; Valadão et al., 2002; de Oliveira et al., 2004; Rocha et al.,
2013). Although the exact function of the SMYB1 protein in this
parasite has not been determined, results presented by Valadão
et al. (2002) and Rocha et al. (2013) suggested that, while SMYB1
may not act directly as a transcription factor, this protein may
be necessary for the regulation of S. mansoni gene expression.
These studies suggest that SMYB1 can function in the turnover,
transport, and stabilization of RNA molecules, acting as RNA
chaperones (Valadão et al., 2002; de Oliveira et al., 2004; Rocha
et al., 2013). Although intracellular proteins are not usually the
first choice of immunogens for vaccination, several extracellular
S. mansoni proteins have been previously tested with moderate
success. We have therefore decided to test SMYB1 as a vac-
cine candidate against this parasite. To address this matter, we
have used Bioinformatics tools to investigate SMYB1 sequence
composition and structural features. We have further evaluated
the protective efficacy of vaccination with recombinant SMYB1
(rSMYB1) against the S. mansoni infection in the murine model.
MATERIALS AND METHODS
ETHICS STATEMENT
Animal experiments were conducted in accordance with Brazilian
Federal Law number 11,794, which regulates the scientific use
of animals, and United States Institutional Animal Care and Use
Committee (IACUC) guidelines. All protocols were approved by
the Ethics Committee for Animal Experimentation (CETEA) at
Universidade Federal deMinas Gerais under the protocol number
203/2011.
IN SILICO SEQUENCE ANALYSIS
National Center for Biotechnology Information (NCBI) BLAST
(Altschul et al., 1990) searches using blastp and PSI-BLAST algo-
rithms were performed against the UniProtKb database (The
UniProt Consortium, 2013) using SMYB1 as query to identify
possible SMYB1 paralogs with 90% minimal similarity. All sub-
sequent analyses were performed for each of the three identified
SMYB isoforms.
Online programs were used to assess functional characteris-
tics of SMYB1. The InterProScan (Zdobnov and Apweiler, 2001)
tool was used to recognize different protein signatures (represent-
ing protein domains, families, and functional sites) with default
parameters. In addition, each SMYB protein isoform was sub-
jected to a conserved domain search (CDS tool) (Marchler-Bauer
and Bryant, 2004) from NCBI. Searches were performed against
the conserved domain database (CDD v3.10; Marchler-Bauer
et al., 2011) with e-values of either 0.01 or 0.001 and with or
without applying the low complexity filter. The CDS analysis also
points out the known DNA and RNA binding sites present within
the predicted domain, by comparing to other proteins that bear
the same domain.
The PredictProtein website (Rost et al., 2004) was used to gen-
erate information about the protein sequence. Several protein
features can be assessed through this webserver, including amino
acid composition, predicted protein binding sites and the effect of
amino acid substitution. We have submitted all SMYB sequences
to the PredictProtein server and retrieved specifically these three
results. Protein binding sites are predicted by a machine-learning
algorithm indirectly based on 3D structures to identify inter-
acting residues using only the protein sequence as input. The
effect of amino acid substitutions for each position is analyzed
by exchanging the residue in each position by all other possibil-
ities and investigating the structural/functional effect upon the
protein as a whole. The impact of each point mutation is mea-
sured by a trained classifier algorithm that takes into account
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several features, most importantly from evolutionary informa-
tion retrieved from sequence alignments. The final output of
this method is presented as a heatmap, in which each column
represents one position in the protein sequence and each row
represents one amino acid. The neutral substitutions are colored
from white to dark green, while non-neutral are colored from
white to dark red. The original amino acid is marked in black.
Intrinsically disordered regions of the three SMYB isoforms
were identified using Disopred (Ward et al., 2004), a trained algo-
rithm that accurately predicts disordered regions by comparison
to a dataset of protein regions that could not be solved by X-ray
crystallography and, therefore, are largely flexible. False positive
rate (FPR) threshold was kept in its default value of 2%.
The secretory or non-secretory nature of the protein was pre-
dicted using SignalP 4.1 (Petersen et al., 2011), which identifies
signal peptides, and the SecretomeP 2.0 server (Bendtsen et al.,
2004), which predicts non-classical protein secretion pathways.
Both types of prediction were performed using a default set-
ting score of 0.5. The Euk-mPLoc 2.0 (Chou and Shen, 2010)
and TargetP 1.1 Servers (Emanuelsson et al., 2000) were subse-
quently applied to predict the subcellular locations of SMYB1.
GPI-modification sites, mucin type O-glycosylation sites, and N-
glycosylation sites were analyzed using the GPI Prediction Server
version 3 (Eisenhaber et al., 1999), NetOGlyc 4.0 Server (Steentoft
et al., 2013), and NetNGlyc 1.0 (http://www.cbs.dtu.dk/services/
NetNGlyc/), respectively. Predicted serine, threonine, and tyro-
sine phosphorylation sites were obtained using the NetPhos 2.0
Server (Blom et al., 1999).
T and B cell epitopes were predicted based on the amino
acid sequences of SMYB1, using prediction tools located at
the Immune Epitope Database and Analysis Resource (IEDB-
AR), which is a database of experimentally characterized
immune epitopes (i.e., B and T cell epitopes) in humans, non-
human primates, rodents, and other animal species (http://
tools.immuneepitope.org/main/index.html). Linear B cell epi-
topes were predicted using programs that incorporate solvent-
accessible surface area calculations and contact distances into
the prediction of B cell epitope potential along the length of
the protein sequence. These programs consist of the Emini
Surface Accessibility Prediction (Emini et al., 1985), Kolaskar and
Tongaonkar Antigenicity (Kolaskar and Tongaonkar, 1990) and
the BepiPred 1.0 server (Larsen et al., 2006). To predict T cell epi-
topes, neural network-based prediction of proteasomal cleavage
sites (NetChop) (Nielsen et al., 2005) and T cell epitopes (NetCTL
and NetCTLpan) (Larsen et al., 2005; Stranzl et al., 2010) were
employed.
CLONING, EXPRESSION, AND PURIFICATION OF RECOMBINANT
SMYB1
Initially, the SMYB1 cDNA (Accession no. U39883) was cloned
into the pGEM-T Easy vector (Promega). The YB1fwNdeI (5′-
CATATGGCGGACACTAGACC-3′) and YB1revHindIII (5′-
AAGCTTGATCAGAGAATTTTAAGCGTC-3′) primers were
used for SMYB1 amplification from adult worm cDNA, gener-
ating an amplification product of 675 bp. The parameters for
the PCR reaction were as follows: 1 cycle at 95◦C for 6min
followed by 25 cycles of 1min at 95◦C, 1min at 58◦C, 1min
at 72◦C and a final cycle of 5min at 72◦C. The recombinant
pGEM-SMYB1 vector was then digested with the enzymes NdeI
and HindIII and the recovered insert was subcloned into the
pET28aTEV vector, in-frame with the six histidine N-terminal
(6xHis) tag. DNA sequencing was performed to confirm the
presence and the correct orientation of the SMYB1 cDNA.
Escherichia coli BL21 was transformed with the recombinant
plasmid (pET28a-SMYB1) and grown in Circlegrow medium
(MP Biomedicals) supplemented with kanamycin (100μg/ml),
at 37◦C, 180 rpm. Bacterial growth was monitored at OD600 nm
until reach 0.4–0.6 and the expression of rSMYB1 was induced
by the addition of 0.5mM IPTG. After 4 h of induction, the
bacterial cells were harvested by centrifugation at 7690 g for
20min. The pellet was resuspended in 50mL of column buffer
(20mM sodium phosphate; 300mM NaCl; 20mM imidazole,
pH 7.4; 10% glycerol). Lysozyme (100μg/mL) was subsequently
added, and the cells were incubated for 15min. The cells were
then subjected to 3 cycles of heat shock (−80◦C/37◦C), followed
by three 15 s cycles of sonication (Fisher Scientific) and three
rounds of centrifugation at 5940 g for 20min. The protein was
purified from the supernatant by affinity chromatography on
a HisTrap HP 5mL Ni-Sepharose column (GE Healthcare)
under denaturing conditions using the ÄKTA Prime Plus Liquid
Chromatography System (GE Healthcare), according to the
manufacturer’s instructions. Fractions containing rSMYB1 were
dialyzed against Tris-NaCl buffer (50mM Tris; 20mM NaCl, pH
7.4), which was changed every 12 h. The dialysis was performed
for 36 h at 4◦C using a >12 kDa dialysis tubing cellulose mem-
brane (Sigma Aldrich). The protein was aliquoted and stored
at −80◦C until use. Protein concentration was determined using
Bradford’s method (Bradford, 1976). The recombinant protein
was used as an antigen for immunization and in immunological
experiments.
SDS-PAGE AND IMMUNOBLOTTING
SDS-PAGE of purified rSMYB1 was performed using 12% gels,
and the gels were electroblotted onto nitrocellulose membranes
for 30min at 20V using a semi-dry system (Bio-Rad). The
membranes were blocked with phosphate-buffered saline (PBS)
(130mM NaCl, 2mM KCl, 8mM Na2HPO4, 1mM KH2PO4)
plus 0.05% Tween 20 (PBS-T) containing 5% dry milk (p/v) for
16 h at room temperature. Themembrane was subsequently incu-
bated in 1:2000 dilutions of an anti-His antibody (GEHealthcare)
and peroxidase-conjugated anti-mouse IgG (Sigma Aldrich) in
PBS-T for 1 h at room temperature. After washes using PBS-T, the
membrane was developed using 3,3′-diaminobenzidine (Sigma
Aldrich), according to the manufacturer’s protocol. After devel-
oping, the membrane was washed using distilled water and dried
on filter paper.
IMMUNIZATION OF MICE AND MEASUREMENT OF SPECIFIC
ANTI-rSMYB1 ANTIBODIES
Female C57BL/6 mice (n = 10, per group) between 6 and 8
weeks of age were obtained from the Universidade Federal de
Minas Gerais (UFMG) animal facility and supplied with com-
mercial food and water ad libitum. Mice were subcutaneously
injected in the nape of the neck with 25μg of rSMYB1 on days
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0, 15, and 30. The vaccine was formulated with the recombinant
protein emulsified in complete Freund’s adjuvant (CFA) (Sigma
Aldrich) for the first immunization and incomplete Freund’s
adjuvant (IFA) (Sigma Aldrich) for subsequent immunizations.
In the control group, Tris-NaCl buffer with Freund’s adjuvant was
administered using the same immunization protocol.
On the tenth day after each immunization, blood was collected
from each experimental group by retro-orbital bleeding. The lev-
els of specific anti-rSMYB1 antibodies were measured by indirect
ELISA. Briefly, Maxisorp 96-well microtiter plates (Nunc) were
coated with 5μg/mL rSMYB1 in carbonate-bicarbonate buffer,
pH 9.6, for 16 h at 4◦C. The plates were then blocked for 2 h at
room temperature with 200μl of PBS-T plus 10% fetal bovine
serum (FBS) (Life Technologies) per well. The serum from each
mouse was diluted 1:100 in PBS-T, and a 100-μl sample was
added to each well and incubated for 1 h at room temperature.
Plate-bound antibody was detected using peroxidase-conjugated
anti-mouse IgG, IgG1, and IgG2a (Sigma Aldrich) diluted to con-
centrations of 1:5000, 1:10000, and 1:2000 in PBS-T, respectively.
Color reactions were developed by the addition of 100μL per
well of 200 pmol o-phenylenediamine (OPD) (Sigma Aldrich) in
citrate buffer, pH 5.0, plus 0.04% H2O2 for 10min. The reac-
tions were stopped with 50μL of 5% sulfuric acid per well.
The plates were read at 492 nm using an ELISA plate reader
(Bio-Rad).
CHALLENGE INFECTION WITH S. MANSONI ANDWORM BURDEN
RECOVERY
Cercariae of S. mansoni (LE strain) were maintained routinely
in Biomphalaria glabrata snails at the Centro de Pesquisas René
Rachou - Fiocruz (CPqRR) and prepared by exposing infected
snails to light for 2 h to induce shedding. Cercariae numbers
and viability were determined using a light microscope prior to
infection. Challenge infection was performed 10 days after the
final immunization. Mice were anaesthetized with 90mg/kg of
ketamine and 10mg/kg of xylazine. The mice abdomens were
shaved and they were exposed percutaneously to 100 cercariae
of S. mansoni in water for 1 h using the ring method (Smithers
and Terry, 1965). Forty-five days after challenge (DAC), the mice
were sacrificed and the adult worms were perfused from the portal
veins (Fonseca et al., 2004). Two independent experiments were
performed to determine protection levels and 10 mice per group
were used.
Protection was calculated by comparing the number of worms
recovered from each vaccinated group with its respective control
group, using the following formula: PL = (WRCG − WREG) ×
100/WRCG, where PL, protection level; WRCG, worms recov-
ered from control group; and WREG, worms recovered from
experimental group.
QUANTIFICATION OF S. MANSONI EGGS RETAINED IN THE LIVER
Quantification of S. mansoni eggs retained in the liver was per-
formed according to the protocol described by Cheever (1968).
To count the number of eggs in the liver, the organ was recov-
ered from each experimental mouse, weighted and placed into
20mL of a 5% KOH solution (p/v) in a 50mL tube. Digestion
occurred at room temperature for 48 h, and the samples were
subsequently mixed thoroughly. The solutions were centrifuged
for 3min at 200 g, and the pellets were resuspended in 20mL PBS
and vortexed. This step was repeated three times. After the last
wash, eggs were resuspended in 5mL of 10% buffered formalde-
hyde in PBS and maintained at room temperature until counting.
An average of three counts was obtained per 50μL solution to
estimate the number of eggs per gram of tissue. Protection was
calculated by comparing the number of eggs recovered from
the vaccinated group to the number of eggs recovered from its
respective control group, using the same formula used for adult
worms.
HEPATIC GRANULOMA ANALYSIS
Liver sections from mice of control and vaccinated groups and
infected with 100 cercariae were collected 45 days post-infection
to evaluate the effect of immunization in granuloma formation.
The liver sections removed from the central part of the left lat-
eral lobe were fixed with 10% buffered formaldehyde in PBS.
Histological sections were performed using microtome (4μm)
and stained in a slide with Gomory’s trichromic. The granulo-
mas were counted in Axiolab Carl Zeiss microscope using 10×
objective lens. All slides were digitized by the Canon Lide 110
scanner, in 300 dpi resolution. The pixels of each histological sec-
tion were fully screened, with subsequent creation of a binary
image and the total area of the cut was calculated. The area of
the lower cutoff was used as a minimum standard of tissue to be
statistically analyzed. The results were expressed by the number
of granulomas per area of liver (mm2). The area of granulomas
was obtained through the KS300 software contained in Carl Zeiss
image analyzer. Fifteen granulomas from each mouse with a sin-
gle well-defined egg were randomly chosen at a microscope with
20× objective lens and scanned through a Q-Color3microcamera
(Olympus). Using a digital pad, the total area of granulomas was
measured and the results were expressed in square micrometers
(μm2).
HUMORAL RESPONSE AGAINST rSMYB1 AND S. MANSONI ANTIGENS
AFTER CHALLENGE
Following immunization, blood was collected using the previ-
ously described protocol (see section Immunization of Mice and
Measurement of Specific anti-rSMYB1 Antibodies) at day 0 (i.e.,
challenge) and day 45 of infection (i.e., sacrifice). Measurements
of specific anti-SMYB1, anti-Schistosoma worm antigen protein
(SWAP), and anti-soluble egg antigen (SEA) IgG, IgG1, and IgG2a
antibodies in the sera were performed using indirect ELISA, as
previously described.
STATISTICAL ANALYSIS
Statistical analysis was performed using Student’s t-test in the
GraphPad Prism 5.0 software package (La Jolla, CA, USA).
RESULTS
IN SILICO ANALYSES OF SMYB1 SEQUENCE
In S. mansoni, the SMYB1 protein (predicted molecular
weight: 23805.20Da, theoretical pI: 10.21) is encoded by
the Smp_097800 gene, which produces three transcript iso-
forms: Smp_097800.1 (SMYB1), Smp_097800.2 (SMYB2), and
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Smp_097800.3 (SMYB3) derived from alternative splicing
(Figure 1A). BLAST searches using blastp and PSI-BLAST
algorithms against the UniProtKb database revealed a paralog
protein in S. mansoni (SMYBX_putative), encoded by the
Smp_097750 gene, which produces a single transcript isoform
(Smp_097750.1) (Figure 1B). Global alignment shows that the
SMYB proteins are much conserved (more than 90% identity).
The N-terminal region (CSD) is more conserved among all
sequences, consistent with the fact that all Smp_097800 derived
isoforms share the first 156 amino acids, and only diverge in their
C-terminal domain. Interestingly, the Smp_097750 derived iso-
form has an almost perfectly conserved CSD region (Figure 1C).
The InterProScan tool identified an N-terminal nucleic acid-
binding OB-fold domain (IPR012340) in the SMYB isoforms
(Figure 1C and Figure S1), which is found in the Y-box bind-
ing protein subfamily (PTHR11544:SF6). The presence of this
domain was also confirmed by the CDS tool with high confidence
(e-vaule of 0.001). The CDS tool has also identified a C-terminal
FIGURE 1 | Comparison between SMYB1 and other SMYB isoforms. The
coding sequences for all SMYB proteins were aligned to two segments of
the S. mansoni genome scaffold 000610, in order to identify exonic and
intronic portions of the genes. Genes are represented by gray bars, while
exons are represented by colored boxes and introns by connecting lines.
Numbers depicted on the gray bars are relative to nucleotide positions and
numbers below the exons are relative to amino acid positions on the
resulting protein sequence. (A) For SMYBX (Smp_097750), there are three
exons and the third (C-terminal, blue box) one is separated from the first two
(dark green and yellow boxes) by a very long intron. (B) Regarding its
paralogs SMYB1 (Smp_097800.1) is formed by four exons and the first two
(green and orange boxes) are shared with isoforms SMYB2 (Smp_097800.2,
with one extra nucleotide at the end of the second exon) and SMYB3
(Smp_097800.3). While the SMYB2 isoform contains an exon (light blue box)
similar to SMYB1 exon 4 (navy blue box), but longer (and in a different
reading frame), SMYB3 contains a third exon (light red) which is similar to
SMYB1 exon 3 (dark red), but longer. (C) Muscle alignment of SMYB1
(Q27277), SMYB2 (G4LXD2), SMYB3 (G4LXD0), and the SMYBX_putative
(G4LXC4). Disordered regions are highlighted in red, according to Disopred
predictions and the conserved domain is underlined in blue.
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API5 domain (apoptosis inhibitor domain 5) approximately
localized between residues 140 and 200 on the longer isoforms
(SMYB1 and SMYB3) although with low confidence (e-value of
0.01). Further analysis may confirm this as an actual conserved
domain or just an artifact (Figure S1).
The prediction of intrinsically disordered regions has charac-
terized SMYB isoforms as mostly disordered proteins. It is inter-
esting to observe that the conserved CSD is located away from the
disordered regions (Figure S1). An additional region where the
disorder probability suddenly drops (flanking the residue 180)
is an interesting feature to be further investigated (Figure S1).
Another interesting finding regarding the disorder is its relation
to protein-binding residues. For all isoforms, predicted protein
binding sites range from residues 1 to ∼25, ∼110 to the end of
the sequence and position 65, which is the only predicted binding
site out of the disordered region (Figure S1 and Supplementary
Material).
When observing the SNAP results presented in Figure S1, one
can easily identify the first ∼20 N-terminal residues as predicted
to contribute very little to the structure and function of SMYB
isoforms, since all simulated mutation in such positions seem to
have no effect to the proteins. On the other hand, the region where
the CDS domain is located is the most important and mutations
in this region can easily have a negative effect to protein structure
and function. This is expected, since this is the only structured
region of the proteins. Accordingly, the nucleic acid binding site
regions are the most conserved within this domain, since the
heatmap is dark red around these sites.
SMYB1 was predicted to be located in the cytoplasm and
nucleus of S. mansoni cells, using the Euk-mPLoc program.
No cleavage sites or N-terminal presequences consistent with
a mitochondrial targeting peptide or secretory pathway signal
peptide were identified using the TargetP Server. In addition,
the SecretomeP server revealed SecP scores below the cutoff
score (0.50), indicating a low possibility of secretion by the
non-classical pathway.
Additional Bioinformatics analyses of domain prediction, pro-
tein disorder, protein structure, and molecular interactions, as
well as putative post-translational modifications (GPI modifica-
tion, glycosylation, and phosphorylation sites) and B-cell and
T-cell type epitope predictions for SMYB1 are presented and
briefly discussed in the Supplementary Material (Table S1 and
Figures S1, S2).
EXPRESSION AND PURIFICATION OF RECOMBINANT SMYB1
The SMYB1 gene was cloned into the pET28a expression vec-
tor, and the recombinant protein was successfully expressed as
a 6xHis tag fusion protein. The transformed bacterial cells were
treated with lysozyme, submitted to heat shock and sonication
treatments, and the lysates were separated into soluble and insol-
uble fractions (Figure 2A). The protein was purified from the
soluble fraction by affinity chromatography using His-binding
columns under denaturing conditions (Figure 2B). The pro-
tein was then refolded by dialysis against Tris-NaCl buffer, with
an approximate yield of 11mg of protein/liter. The purity of
the recombinant SMYB1-6xHis tag fusion protein was assessed
using SDS-PAGE and Western blotting analysis with an anti-His
antibody (Figure 2C), which revealed a protein of approximately
30 kDa.
HUMORAL RESPONSES TO rSMYB1
C57Bl/6 mice were immunized with three doses of rSMYB1
formulated with Freund’s adjuvant, and the level of specific anti-
rSMYB1 antibodies in the sera from the immune and placebo
groups was evaluated using ELISA (Figure 3). Significant levels
(p < 0.01) of specific anti-rSMYB1 IgG antibodies were detected
after the first immunization, and these antibodies remained at
a high levels after the second and third immunizations. To
FIGURE 2 | Expression and purification of rSMYB1 as a 6xHis fusion
protein. (A) Coomasie blue-stained 12% SDS-PAGE profile of E. coli BL21
expressing the pET28a-SMYB1 construct. Lanes: (1) lysate of induced
culture—0h; (2) lysate of induced culture—1h; (3) lysate of induced
culture—2h; (4) lysate of induced culture—3h; (5) lysate of induced
culture—4h; (6) soluble fraction (SF) of induced culture lysate; (7) molecular
weight marker (BenchMark Protein Ladder, Invitrogen); (8) non-soluble
fraction of induced culture lysate (pellet). (B) Coomasie blue-stained 12%
SDS-PAGE profile of the fractions of purified recombinant SMYB1. Lanes
(1–4) SMYB1 fractions; lane (5) molecular weight marker (BenchMark Protein
Ladder, Invitrogen). (C) Western blotting analysis of purified recombinant
SMYB1 using an anti-His antibody (GE Healthcare). Lane (1) molecular weight
marker (Amersham Full Range Rainbow Molecular Weight); lane (2) purified
rSMYB1.
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determine the isotype of the antibody produced after immuniza-
tion, IgG1 and IgG2a antibodies specific to rSMYB1 were also
analyzed. The results revealed that rSMYB1 stimulates an IgG1
antibody response (p < 0.05) after the second dose (Figure 3). In
the placebo group, no significant differences in specific IgG, IgG1,
or IgG2a antibody levels were observed after immunization (data
not shown).
S. MANSONI ADULT WORM RECOVERY
To determine the protective potential of rSMYB1, immunized
mice were challenged with 100 S. mansoni cercariae. The worms
were recovered by perfusion 6 weeks after challenge, and the
results were expressed as the mean worm burden (mean ± SD)
as presented in Table 1. The animals immunized with rSMYB1
in Freund’s adjuvant exhibited a 26% reduction in adult worm
burden recovered from the mesenteric veins when compared
to the control group (p > 0.05). No differences in male/female
proportion were observed between the placebo and immune
groups (data not shown). Similar results were observed in two
independent experiments.
FIGURE 3 | Kinetics of specific anti-rSMYB1 IgG, IgG1, and IgG2a
antibodies in sera from mice vaccinated with rSMYB1. Sera were
collected from 10 immunized mice per group prior to the first immunization
and at days 10, 25, and 40 after the first immunization and assayed by
ELISA. The results are presented as the mean absorbance at 492 nm for
each isotype on each day of sera collection. Asterisks indicate statistically
significant differences between the vaccinated and preimmune groups:
∗p < 0.05; ∗∗p < 0.01. Black bars: IgG antibody. Gray bars: IgG1 antibody.
White bars: IgG2a antibody. The results are representative of two
independent biological replicates.
Table 1 | Worm burden and protection level in mice vaccinated with
the rSMYB1 protein.
Group Worm burden Protection
(mean ± SD)
Tris-NaCl + CFA/IFA (placebo) 51.50 ± 26.64 –
rSMYB1 + CFA/IFA (immune) 38.11 ± 10.78 26%
CFA, complete Freund’s adjuvant; IFA, incomplete Freund’s adjuvant. No statisti-
cally significant differences were observed between groups (p > 0.05). The data
are representative of two independent biological assays.
QUANTIFICATION OF S. MANSONI EGGS RETAINED IN THE LIVER
In addition to worm counting, we evaluated the number of S.
mansoni eggs retained in each gram of liver. The immunized
group retained 28% less eggs in the liver than the placebo group
(p > 0.05) (Figure 4). We have also measured the number of eggs
layed by female adult worm recovered before and after immuniza-
tion and found a 5.5% decrease in the number of eggs per female
on the immunized group (the average was of 769.20 eggs/female
on the placebo group against 726.69 eggs/female on the immu-
nized group). Therefore, these result points to a combination
between diminished egg production per female and decreased
number of adult parasites in the host after immunization.
HISTOPATHOLOGICAL ANALYSIS
Histopathological analysis showed significantly fewer granulo-
mas in the liver of animals immunized with rSMYB1 (p < 0.05)
(Figure 5A). An associated decrease in the area of granulomas
in the immunized mice group compared to the placebo group
(p < 0.05) was also observed (Figures 5B, 6). However, no sig-
nificant decrease in the area of fibrosis was detected when the two
groups were compared (p > 0.05) (Figure 5C).
HUMORAL RESPONSE AGAINST rSMYB1 AND S. MANSONI ANTIGENS
AFTER CHALLENGE
Levels of specific antibodies produced in response to the purified
rSMYB1 protein in each group of mice after challenge were deter-
mined using ELISA. Surprisingly, the levels of rSMYB1-specific
IgG, IgG1, and IgG2a antibodies in the immune group decreased
after the third dose of the vaccine (p > 0.05) (Figure 7). In
contrast, the placebo group exhibited increased levels of all anti-
bodies against the protein. No statistically significant differences
were observed between the immune and placebo groups at 45
FIGURE 4 | Counting of the number of S. mansoni eggs retained in the
liver of immunized mice. The number of S. mansoni eggs in 10 mice
immunized with Tris-NaCl + adjuvant (placebo group) or with rSMYB1 +
adjuvant (immune group) were counted. The infection developed for 45
days prior to sacrifice. The liver was digested for 48 h in a 5% KOH solution
(p/v), and the eggs were maintained in 10% buffered formaldehyde until
counting. The results are presented as the mean number of eggs per gram
of liver. No statistically significant differences were observed between
groups (p > 0.05). The results are representative of two independent
biological experiments.
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FIGURE 5 | Liver pathology measured in rSMYB1 vaccinated mice. (A) Number of granuloma per area of liver (mm2), (B) area of granuloma (μm2), and (C)
area of fibrosis (μm2) were measured in rSMYB1 immunized mice and control group. Data are expressed as means ± SD.
FIGURE 6 | Histological analysis of liver tissue from mice immunized
with rSMYB1. Animals were sacrificed 45 days post-infection and their
livers were washed with PBS and stored in formaldehyde until histological
procedures. Fixed livers were sliced using microtome (4μm) and stained
with Gomory’s trichromic. (A) Liver from the control group and (B) liver
from rSMYB1 immunized mice. Scale bar: 50μm. The granulomas were
counted in Axiolab Carl Zeiss microscopy using 10× objective lens.
DAC (p > 0.05). The observed anti-rSMYB1 IgG1/IgG2a ratio
decreased in the immunized mice.
To measure IgG, IgG1, and IgG2a antibodies against the spe-
cific S. mansoni antigens SWAP and SEA, the sera from vaccinated
mice in each group were tested using ELISA (Figure 7). No spe-
cific anti-SWAP and anti-SEA IgG, IgG1, and IgG2a antibodies
were detected before or during the immunizations (data not
shown). After challenge, both groups developed significant lev-
els of specific anti-SWAP and anti-SEA (Figure 7) IgG antibodies
(p < 0.01). With respect to isotype, both groups developed a pre-
dominantly IgG1 antibody response (p < 0.05) against the SWAP
antigen but not against the SEA antigen. No differences in IgG2a
antibody response against these antigens were observed between
the immune and placebo groups.
DISCUSSION
The long-term effective control of schistosomiasis will only occur
as a result of combined vaccination and chemotherapy strate-
gies with sanitation and public health control measures. Although
evidences indicate that chemotherapy using praziquantel is effec-
tive in reducing the intensity of infection, as reinfection has been
observed after chemotherapy, the use of this control strategy alone
has been questioned (Wilson and Coulson, 2006). The irradiated
cercarial vaccine elicits >80% protection in rodents and pri-
mates and other antigens identified in analyses of the Schistosoma
proteome, transcriptome, glycome, and immunome, also exhibit
protective potential (Oliveira et al., 2008). Nevertheless, the effec-
tiveness of recombinant vaccines rarely exceeds 40% (McManus
and Loukas, 2008; McWilliam et al., 2012), although new find-
ings from El Ridi and collaborators (El Ridi and Tallima, 2013;
El Ridi et al., 2014) are promising and depict a decrease of ∼70–
80% in worm burden using papain as adjuvant and focusing on
S. mansoni cysteine peptidases as antigens.. To date, vaccine can-
didates have been assessed using omics-derived high throughput
approaches, such as proteomics, immunomics, and vaccinomics
with promising results (DeMarco and Verjovski-Almeida, 2009;
Loukas et al., 2011; McWilliam et al., 2012).
Many studies focus on tegument proteins as potential
drug/vaccine targets because the tegument is a dynamic layer
that represents the primary host-parasite interface and has close
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FIGURE 7 | Kinetics of specific anti-rSMYB1, anti-SWAP and anti-SEA
IgG, IgG1, and IgG2a antibodies. The presence of antibodies was
measured in sera from 10 mice immunized with Tris-NaCl + adjuvant
(placebo group) or with rSMYB1 + adjuvant (immune group). Sera were
collected prior to sacrifice 45 days after challenge and assayed by ELISA.
The results are presented as the mean absorbance at 492 nm for each
immunoglobulin isotype. Asterisks indicate statistically significant
differences between the vaccinated and pre-immune groups: ∗p < 0.05,
∗∗p < 0.01. DAC, days after challenge. Black bars: IgG antibody. Gray bars:
IgG1 antibody. White bars: IgG2a antibody. The results are representative
of two independent biological experiments.
proximity to the host blood and immune system (Jones et al.,
2004; Pearce and Freitas, 2008; DeMarco and Verjovski-Almeida,
2009; Han et al., 2009; Loukas et al., 2011). Other studies focus
on excretory/secretory (ES) proteins, molecules known to be
released from live worms in the tissue culture and that may be
secreted into host tissues as the parasites move along the host
body, feed, and produce eggs (Loukas et al., 2011). According
to McManus and Loukas (2008), the apical membrane proteins
expressed on the surfaces of the schistosomulum and the adult
worm are the preferred vaccine targets. Therefore, the use of
extracellular antigens for vaccine production is accompanied by
inherent problems, for instance, the difficulty to produce recom-
binant proteins, since the majority of these antigens is processed
through the classical secretory pathway and is subject of com-
plex post-translational modifications, (e.g., glycosylation, specific
processing, and disulfide bonds formation). Additionally, most
antigens tested in WHO trials and by other groups are cytoso-
lic or cytoskeletal components (e.g., paramyosin, Sm14, and GST)
(Wilson and Coulson, 2006;McManus and Loukas, 2008; Oliveira
et al., 2008). To our knowledge no study exploring the poten-
tial of a nucleic acid-binding protein as a S. mansoni vaccine
candidate has been published. This is the first attempt to char-
acterize such a protein as an antigen and to evaluate its protective
efficacy as a vaccine against S. mansoni infection in the murine
model.
In 2005, Carl and collaborators have stated that most nuclear
systemic autoantigens contain long regions of structural disorder.
They have studied properties of intrinsically disordered proteins
in order to make connections linking disorder to antigenicity.
The authors state that the amino acid composition of disordered
regions (usually rich in Arg, Gly, Ser, Pro, Glu, Lys, Gln, and Ala
residues) leads to a highly charged and low complexity molecule,
typical properties of autoantigens (Plotz, 2003). Another property
of autoantigens is their capacity to bind nucleic acids, as described
by Plotz and cited by Carl and collaborators. Additionally, Plotz
listed phosphorylation as a strong feature of autoantigens. All of
these factors, namely enrichment in six of the listed amino acids
(Arg, Gly, Ser, Pro, Glu, Lys), low complexity regions (such as
repetitive sequence patterns), nucleic acid binding capacity and
the abundance of phosphorylation sites (10 predicted) can be
observed in the SMYB1 protein, thus corroborating its putative
antigenic potential.
Although the Euk-mPLoc program predicted the SMYB1
localization in the cytoplasm and nucleus of cells, our group
has previously demonstrated that this protein is predominantly
located in the cytoplasm of cells from different life cycle stages
of S. mansoni, suggesting that SMYB1 is probably acting in
RNA metabolism in the cytoplasm. We also showed the pres-
ence of SMYB1 near the tegument in adult worms proposing
an action on the translational regulation of tegument pro-
teins (Rocha et al., 2013). Intrinsically disordered proteins have
recently been characterized as the prevalent type of RNA and
protein chaperones (Tompa and Csermely, 2004). Accordingly,
it has been shown that YBPs and other cold-shock proteins
typically act as chaperones that maintain mRNA in a single-
stranded conformation to sustain the expression of genes that
are necessary for cell growth, proliferation, and transforma-
tion (Jiang et al., 1997; Matsumoto and Wolffe, 1998; Salvetti
et al., 1998; Tanaka et al., 2004; Evdokimova et al., 2006). YBPs
are thought to play roles in a wide variety of responses to
environmental stresses (Kohno et al., 2003). As such, SMYB1
localization in the cytoplasm of tegumental cells reinforces its
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importance as a protein that acts responding to the stressing host
environment.
Molecules that contain signal peptides or signal anchors
are predicted to be excreted, secreted or membrane-anchored,
directly interacting with the host immune system and, as stated
above, constitute relevant targets for schistosome vaccines. The
combined Bioinformatics results obtained in this study suggest
that the SMYB1 protein is not secreted. However, Frye et al.
(2009) reported that human YB-1 is secreted from cells dur-
ing inflammatory stress after treatment with lipopolysaccharide,
hydrogen peroxide or TGFβ. In these cases, YB-1 is secreted
not via the classical mechanism of protein secretion (i.e., via
the Golgi apparatus and endoplasmic reticulum) but by a non-
classical mechanism inside endolysosomal vesicles (Frye et al.,
2009; Eliseeva et al., 2011). The question of whether SMYB1 is
secreted or not needs further experimental investigation.
We reported here the successful cloning of SMYB1 cDNA
into the pET28a vector and the expression of rSMYB1 in the
soluble fraction of bacterial lysates. The discrepancy between
the ∼30 kDa protein molecular mass value calculated from
SDS-PAGE and the ∼24 kDa protein molecular mass value pre-
dicted from the cDNA is typical of Y-box proteins and related
to the anomalous electrophoretic properties of these proteins
(Deschamps et al., 1992) or to post-translational modification,
such as phosphorylation (Salvetti et al., 1998). We subsequently
evaluated the antigenicity of the protein by investigating the
murine humoral immune response to rSMYB1 and the impact
of its immunization on adult worm and egg burden in mice chal-
lenged with 100 cercariae of S. mansoni. Recent data suggested
that the establishment of a robust humoral response is likely
the key for generating maximal immunity against schistosomes
(Wynn and Hoffmann, 2000). A primary obstacle to the develop-
ment of a schistosome vaccine is the lack of available knowledge
concerning the type of immune response that should be induced.
In the irradiated cercariae vaccination model, above 80% protec-
tion can be granted by a Th1, a Th2, or a mixed Th1/Th2 immune
response (Wynn and Hoffmann, 2000). However, with respect to
recombinant proteins, Th1-inducing antigens have been reported
to confer protection against Schistosoma infection in the mouse
model (Jankovic et al., 1996; Mountford et al., 1996; Zhang et al.,
2001; Fonseca et al., 2004; Varaldo et al., 2004; Li et al., 2005;
Cardoso et al., 2008; Garcia et al., 2008).
In this study, C57Bl/6 mice immunized with rSMYB1 exhib-
ited high levels of specific anti-SMYB1 IgG antibodies that
emerged after the first immunization. Specific anti-SMYB1 IgG1
antibodies predominated over IgG2a antibodies, particularly after
the second immunization. However, the IgG1/IgG2a ratio was
reduced after the last immunization (i.e., during the challenge
period). Antibody levels correlated with protective efficacy in our
study. The antibody levels developed by mice immunized with
rSMYB1 reduced in 26% the number of adult worm burden and
in 28% the eggs/granuloma trapped in the liver. A critical issue
in vaccine design is the use of an appropriate adjuvant to induce
the suitable immune response. Although the CFA adjuvant, which
triggers a Th1 response, cannot be used in humans (Heegaard
et al., 2011), it is widely utilized in initial immunization trials.
Further experiments combining rSMYB1 with suitable adjuvant
formulations for use in humans should be performed. In this
sense, an interesting strategy would be to use papain as adjuvant,
given that recently published articles have described very high
protection rates related to the use of such molecule in vaccine
candidates (El Ridi and Tallima, 2013; El Ridi et al., 2014).
S. mansoni adult worms live in the blood essentially unrecog-
nized for many years, whereas schistosome eggs are a prominent
target of the host immune response. In the first weeks of murine
S. mansoni infection, a Th1 immune response is observed and the
eggs deposited in the blood vessels by females that pass to the
endothelial barrier and become trapped in the liver are immedi-
ately targeted by recruited immune cells that consist primarily of
T-cells, eosinophils, and macrophages (Pearce and MacDonald,
2002; Wynn et al., 2004). Histopathology results show that in
the initial phase of infection vaccination with SMYB1 seems
to interfere with cell recruitment and migration in the liver.
Consequently, the resulting granulomas, although presenting the
same area of fibrosis, were fewer when compared to unvaccinated
animals, showing the protective potential of the protein in the
initial liver pathology.
Although tegument proteins are considered the main targets
for vaccine development (Bergquist et al., 2002; McManus and
Loukas, 2008), this study demonstrates that a cytoplasmic pro-
tein has the potential to be used as an immunogen, as we showed
that SMYB1 could reduce the load of intestinal worms and eggs
retained in the liver when it was used in vaccination trials and also
that the protection levels achieved by SMYB1 are comparable to
those obtained with other tegument and cytoskeleton proteins.
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